Navigation Links
Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death

dence of cardiovascular hospitalization and death were comparable for the patients taking the Avandia combination and the patients taking the metformin-sulfonylurea combination

GSK remains committed to the fight against diabetes. Avandia is an effective medicine that is a valuable treatment for millions of patients who are using it to control their diabetes, a disease with potentially devastating consequences if left unmanaged.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline on the World Wide Web at http://www.gsk.com .

Important Safety Information for Avandia(R) (rosiglitazone maleate)

Avandia, along with diet and exercise, helps improve blood sugar control. It may be taken alone or with other diabetes medicines. For some people taking Avandia, possible side effects include heart failure or other heart problems. Further information regarding potential heart-related risks is currently under review by the FDA.

Talk to your doctor as FDA has made information on potential heart-related risks available to physicians on its website at http://www.fda.gov. Tell your doctor if you have heart problems or heart failure. Avandia can cause your body to keep extra fluid, which leads to swelling and weight gain. Extra body fluid can make some heart problems worse or lead to heart failure. If you have swelling or fluid retention, shortness of breath or trouble breathing, an unusually rapid increase in weight, or unusual tiredness while taking Avandia, call your doctor right away.

You should not take Avandia if you have liver problems. Blood tests should be used to check for liver problems before starting and while taking Avandia.
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting

Post Your Comments:
(Date:11/27/2009)...27 ACUO TECHNOLOGIES, developers o...re, data migration tools and services, is pleased ...emark Office has approved a patent application for...Network." Acuo Technologies is pleased to add the ...rty. In general, the granted patent application br...
(Date:11/25/2009)...Nov. 25 Praxis Electronic Medical ...can Academy of Family Physicians, (AAFP) Family Pr... Survey for improving medical quality, health main...new ARRA Stimulus legislation. Praxis also ranked ...ve effect in determining their salary. Finally, Pr...
(Date:11/25/2009)... 25 Hologic, Inc. (Holog...eloper, manufacturer and supplier of premium diagn...cts dedicated to serving the healthcare needs of w...cal Society of North America (RSNA) at McCormick P...009 to highlight our new SecurView(®) DX mult...
Breaking Medicine Technology:Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 43 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 48760 13 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 48760 23 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 48760 33 studies confirm the value of etanercept therapy in treating juvenile idiopathic arthritis 48760 4Over half of people with rheumatoid arthritis have periodontitis 48758 1Over half of people with rheumatoid arthritis have periodontitis 48758 2Over half of people with rheumatoid arthritis have periodontitis 48758 3Appetite stimulating hormone is first potential medical treatment for frailty in older women 48756 1Appetite stimulating hormone is first potential medical treatment for frailty in older women 48756 2
...ust Remain Paramount Concern, SEATTLE, Nov. 7 Th...the following statement today from Executive,Direc...new data from the,STEP AIDS vaccine study by Merck...Infectious Diseases (NIAID) and the HIV Vaccine Tr...meeting today., The data from the STEP study rele...
... analysis,presented today from METEOR (Measuring E... Rosuvastatin) showed CRESTOR(R) (rosuvastatin cal...ma-media thickness (CIMT) in four,patient populati...isease.,The sub- study was conducted in subjects d...aving less than two or two or more risk factors (R...
Other Medicine Technology:AIDS Vaccine Advocacy Coalition Calls for AIDS Vaccine Field to Work Together to Analyze STEP Study Data and Determine Best Course to Move Forward 2AIDS Vaccine Advocacy Coalition Calls for AIDS Vaccine Field to Work Together to Analyze STEP Study Data and Determine Best Course to Move Forward 3New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 2New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 3New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 4New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 5New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 6
(Date:11/27/2009)...s may reduce future disease burden, researchers sa...- Encouraging city dwellers to walk and bicycle in...c health benefits than increased used of low-emiss...e study compared the projected health effects in 2...for London, England, and Delhi, India: business-a...
(Date:11/27/2009)...urers who use medical load cells at the heart of t...inging in technology partner Flintec early in the ...edical manufacturers are calling in Flintec load c..., ensuring that progress will not be constrained b...d technology. , (PRWEB) N...
(Date:11/26/2009)...date (TM) has been shown in studies to be effectiv...used by an overload of copper, and certain metasta...ver, is known about how the drug works at the mole...niversity researchers now has provided an invaluab...nd to copper-loaded metallochaperones. The drug se...
(Date:11/26/2009)...ental (RTDental), a leading dental group practice ...ansion of its services to include LUMINEERS by a c... , Durham, NC (PRWEB) -- R...t Dr. Doug Macmillan, an experienced LUMINEERS D...training seminar. RTDental’s ability to ful...
(Date:11/25/2009)...Newswire-FirstCall/ -- Onyx Pharmaceuticals, Inc...y will host two investor events in December: ,,... a.m. CT/10:00 a.m. ET ,, Principal investiga...arfilzomib in relapsed and/or refractory multiple ...of Hematology (ASH) Annual Meeting and Exposition ...
Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...Omnicell,Inc. (Nasdaq: OMCL ), a leading provider...s, announced today that it has completed its $40.0...n Stock. A total of,2,133,898 shares were repurcha...g patient safety and operational efficiency in,hea...
...ll Changes Can Have a Big Effect on ..., N.J., March 12 Chef, nutritionist,and cookbook ...ncouraging,people with type 2 diabetes to recogniz... & Co., Inc., Chef LaLa will be,visiting selected ...
..."Superheroes" Theme, WASHINGTON, March 12 The U.... for Healthcare Research and Quality,(AHRQ) joined...anish-language national public service campaign de...ing their doctor for,regular screenings., Hispani...
...Guidance, SUNNYVALE, Calif., March 12 Cepheid (N...website, http://www.cepheid.com, ,comments on a s...ican,Medical Association regarding MRSA screening ...lion and net income,excluding stock compensation e...
...armaceuticals, a division of Wyeth (NYSE: WYE ), ...tional clinical studies to address questions from,... (CHMP) regarding the,risk-benefit profile of desv...venlafaxine for the treatment of,vasomotor symptom...
... March 11,more than 300 individuals with lupus, th...rs of Congress to increase government funding for,...will greatly expand,federal efforts on lupus. The ... lawmakers to increase funding for biomedical rese...
Other Medicine News:Health News:Omnicell Announces Completion of Its Common Stock Repurchase Plan 2Health News:Chef LaLa to Provide Healthy Menu Makeovers 2Health News:Chef LaLa to Provide Healthy Menu Makeovers 3Health News:Chef LaLa to Provide Healthy Menu Makeovers 4Health News:Chef LaLa to Provide Healthy Menu Makeovers 5Health News:AHRQ and Ad Council Encourage Hispanics to Become More Involved in Their Health Care 2Health News:AHRQ and Ad Council Encourage Hispanics to Become More Involved in Their Health Care 3Health News:AHRQ and Ad Council Encourage Hispanics to Become More Involved in Their Health Care 4Health News:Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association 2Health News:Cepheid Comments on Study Regarding MRSA Surveillance Reported in the Journal of the American Medical Association 3Health News:More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms 2Health News:More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms 3Health News:Lupus Advocates Urge Increased Funding for Lupus Research and Education 2
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...ARUP Laboratories is a national reference laborato... research and development. ARUP offers an extensiv...ests in clinical and anatomic pathology. Owned by ... include more than half of the nation's university...
...Macula Complete includes the nutrients used in the...plement Trial (LAST), which suggested no AMD disea...year period. Macula Complete also contains efficac...ed studies to support the mitochondria, as well as...
...Bausch & Lomb PreserVision® Soft Gel Lutein pa...ausch & Lomb PreserVision® AREDS formula, with...Glo Lutein., Lutein is a carotenoid found in dark... highly concentrated in the macula, the part of th...
Medicine Products: